Nurullah İlhan, Associate Professor of Medical Oncology/Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Founder and Head of Medical Oncology Clinic, shared Andrea Boutros’s, Assistant Professor at University of Genoa, post on X, adding:
“Thoughtful summary Andrea Boutros — this slide captures the key momentum in melanoma and skin cancers at ASCO 26 very well.
Particularly striking are the sustained 5-year benefits with the personalized mRNA vaccine (intismeran plus pembrolizumab) showing durable reductions in recurrence and distant metastasis, alongside the advancing neoadjuvant triplet approaches and promising next-gen cell therapies like engineered TIL and PRAME-targeted TCR-T.
These developments point toward increasingly personalized and effective strategies in both resectable and advanced disease. Looking forward to seeing how these mature and translate into practice over the coming years.”
Quoting Andrea Boutros’s post:
“My Best Of ASCO26 highlights for Melanoma and Skin Cancers – Neoadj advancing, next-gen cell therapies, and long-term mRNA vaccine data stealing the show.”
Other articles Andrea Boutros on OncoDaily.